Abstract
BackgroundA key goal in rheumatoid arthritis (RA) therapy is to achieve remission or at least very low disease activity1. Secukinumab, a fully human anti-IL-17A monoclonal antibody has been shown to...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have